Does the media prefer SVRA or KNSA?

In the previous week, Savara and Savara both had 1 articles in the media. Kiniksa Pharmaceuticals International's average media sentiment score of 1.29 beat Savara's score of 0.00 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Savara 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Kiniksa Pharmaceuticals International 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is TNGX or SVRA more profitable?

Tango Therapeutics' return on equity of -41.54% beat Savara's return on equity. Company Net Margins Return on Equity Return on Assets Tango Therapeutics N/A -41.54% -33.44% Savara N/A -87.19% -66.42%

Does the media favor TNGX or SVRA?

In the previous week, Tango Therapeutics had 2 more articles in the media than Savara. MarketBeat recorded 3 mentions for Tango Therapeutics and 1 mentions for Savara. Tango Therapeutics' average media sentiment score of 0.31 beat Savara's score of 0.00 indicating that Tango Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tango Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Savara 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings and valuation, SVRA or EWTX?

Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Savara, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Savara N/A N/A -$118.84M -$0.56 N/A Edgewise Therapeutics N/A N/A -$167.79M -$1.66 N/A

Is SVRA or EWTX more profitable?

Edgewise Therapeutics' return on equity of -32.55% beat Savara's return on equity. Company Net Margins Return on Equity Return on Assets Savara N/A -87.19% -66.42% Edgewise Therapeutics N/A -32.55% -31.04%

Does the media favor SVRA or EWTX?

In the previous week, Edgewise Therapeutics had 2 more articles in the media than Savara. MarketBeat recorded 3 mentions for Edgewise Therapeutics and 1 mentions for Savara. Edgewise Therapeutics' average media sentiment score of 0.13 beat Savara's score of 0.00 indicating that Edgewise Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Savara 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Edgewise Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, VKTX or SVRA?

Savara is trading at a lower price-to-earnings ratio than Viking Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Viking Therapeutics N/A N/A -$359.64M -$4.14 N/A Savara N/A N/A -$118.84M -$0.56 N/A

Is VKTX or SVRA more profitable?

Viking Therapeutics' return on equity of -71.31% beat Savara's return on equity. Company Net Margins Return on Equity Return on Assets Viking Therapeutics N/A -71.31% -65.35% Savara N/A -87.19% -66.42%

Does the media prefer VKTX or SVRA?

In the previous week, Viking Therapeutics had 7 more articles in the media than Savara. MarketBeat recorded 8 mentions for Viking Therapeutics and 1 mentions for Savara. Viking Therapeutics' average media sentiment score of 0.33 beat Savara's score of 0.00 indicating that Viking Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viking Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Savara 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to SVRA or ACAD?

In the previous week, ACADIA Pharmaceuticals had 7 more articles in the media than Savara. MarketBeat recorded 8 mentions for ACADIA Pharmaceuticals and 1 mentions for Savara. ACADIA Pharmaceuticals' average media sentiment score of 1.06 beat Savara's score of 0.00 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Savara 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ACADIA Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Savara (SVRA) Competitors

$6.38 +0.17 (+2.74%)

Closing price 04:00 PM Eastern

Extended Trading

$6.28 -0.09 (-1.49%)

As of 07:12 PM Eastern

Compare

SVRA vs. KNSA, TNGX, EWTX, VKTX, and ACAD

Should you buy Savara stock or one of its competitors? MarketBeat compares Savara with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Savara include Kiniksa Pharmaceuticals International (KNSA), Tango Therapeutics (TNGX), Edgewise Therapeutics (EWTX), Viking Therapeutics (VKTX), and ACADIA Pharmaceuticals (ACAD). These companies are all part of the "pharmaceutical products" industry.

How does Savara compare to Kiniksa Pharmaceuticals International?

Savara (NASDAQ:SVRA) and Kiniksa Pharmaceuticals International (NASDAQ:KNSA) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and risk.

Kiniksa Pharmaceuticals International has higher revenue and earnings than Savara. Savara is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Savara	N/A	N/A	-$118.84M	-$0.56	N/A
Kiniksa Pharmaceuticals International	$677.56M	7.35	$59.01M	$0.90	71.96

87.9% of Savara shares are held by institutional investors. Comparatively, 54.0% of Kiniksa Pharmaceuticals International shares are held by institutional investors. 5.3% of Savara shares are held by company insiders. Comparatively, 52.0% of Kiniksa Pharmaceuticals International shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Kiniksa Pharmaceuticals International has a net margin of 9.69% compared to Savara's net margin of 0.00%. Kiniksa Pharmaceuticals International's return on equity of 13.26% beat Savara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Savara	N/A	-87.19%	-66.42%
Kiniksa Pharmaceuticals International	9.69%	13.26%	9.86%

In the previous week, Savara and Savara both had 1 articles in the media. Kiniksa Pharmaceuticals International's average media sentiment score of 1.29 beat Savara's score of 0.00 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Savara	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kiniksa Pharmaceuticals International	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Savara has a beta of 0.24, meaning that its share price is 76% less volatile than the broader market. Comparatively, Kiniksa Pharmaceuticals International has a beta of 0.07, meaning that its share price is 93% less volatile than the broader market.

Savara currently has a consensus price target of $10.14, suggesting a potential upside of 58.98%. Kiniksa Pharmaceuticals International has a consensus price target of $62.71, suggesting a potential downside of 3.16%. Given Savara's higher probable upside, equities analysts clearly believe Savara is more favorable than Kiniksa Pharmaceuticals International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Savara	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Kiniksa Pharmaceuticals International	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.00

Summary

Kiniksa Pharmaceuticals International beats Savara on 11 of the 14 factors compared between the two stocks.

How does Savara compare to Tango Therapeutics?

Tango Therapeutics (NASDAQ:TNGX) and Savara (NASDAQ:SVRA) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, risk, institutional ownership, profitability and analyst recommendations.

Tango Therapeutics currently has a consensus price target of $41.50, indicating a potential upside of 35.44%. Savara has a consensus price target of $10.14, indicating a potential upside of 58.98%. Given Savara's stronger consensus rating and higher possible upside, analysts clearly believe Savara is more favorable than Tango Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73
Savara	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Tango Therapeutics has a beta of 1.12, suggesting that its stock price is 12% more volatile than the broader market. Comparatively, Savara has a beta of 0.24, suggesting that its stock price is 76% less volatile than the broader market.

Tango Therapeutics' return on equity of -41.54% beat Savara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tango Therapeutics	N/A	-41.54%	-33.44%
Savara	N/A	-87.19%	-66.42%

In the previous week, Tango Therapeutics had 2 more articles in the media than Savara. MarketBeat recorded 3 mentions for Tango Therapeutics and 1 mentions for Savara. Tango Therapeutics' average media sentiment score of 0.31 beat Savara's score of 0.00 indicating that Tango Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tango Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Savara	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Tango Therapeutics has higher revenue and earnings than Savara. Tango Therapeutics is trading at a lower price-to-earnings ratio than Savara, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tango Therapeutics	$62.38M	71.05	-$101.59M	-$0.83	N/A
Savara	N/A	N/A	-$118.84M	-$0.56	N/A

79.0% of Tango Therapeutics shares are owned by institutional investors. Comparatively, 87.9% of Savara shares are owned by institutional investors. 6.5% of Tango Therapeutics shares are owned by insiders. Comparatively, 5.3% of Savara shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Tango Therapeutics beats Savara on 9 of the 15 factors compared between the two stocks.

How does Savara compare to Edgewise Therapeutics?

Savara (NASDAQ:SVRA) and Edgewise Therapeutics (NASDAQ:EWTX) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, media sentiment, earnings, analyst recommendations, institutional ownership, profitability and risk.

In the previous week, Edgewise Therapeutics had 2 more articles in the media than Savara. MarketBeat recorded 3 mentions for Edgewise Therapeutics and 1 mentions for Savara. Edgewise Therapeutics' average media sentiment score of 0.13 beat Savara's score of 0.00 indicating that Edgewise Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Savara	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Edgewise Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Edgewise Therapeutics' return on equity of -32.55% beat Savara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Savara	N/A	-87.19%	-66.42%
Edgewise Therapeutics	N/A	-32.55%	-31.04%

Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Savara, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Savara	N/A	N/A	-$118.84M	-$0.56	N/A
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.66	N/A

87.9% of Savara shares are owned by institutional investors. 5.3% of Savara shares are owned by company insiders. Comparatively, 21.3% of Edgewise Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Savara currently has a consensus target price of $10.14, suggesting a potential upside of 58.98%. Edgewise Therapeutics has a consensus target price of $47.64, suggesting a potential upside of 2.89%. Given Savara's stronger consensus rating and higher possible upside, analysts clearly believe Savara is more favorable than Edgewise Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Savara	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

Savara has a beta of 0.24, meaning that its share price is 76% less volatile than the broader market. Comparatively, Edgewise Therapeutics has a beta of 0.27, meaning that its share price is 73% less volatile than the broader market.

Summary

Edgewise Therapeutics beats Savara on 7 of the 13 factors compared between the two stocks.

How does Savara compare to Viking Therapeutics?

Viking Therapeutics (NASDAQ:VKTX) and Savara (NASDAQ:SVRA) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends, valuation and media sentiment.

76.0% of Viking Therapeutics shares are owned by institutional investors. Comparatively, 87.9% of Savara shares are owned by institutional investors. 5.3% of Viking Therapeutics shares are owned by company insiders. Comparatively, 5.3% of Savara shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Viking Therapeutics had 7 more articles in the media than Savara. MarketBeat recorded 8 mentions for Viking Therapeutics and 1 mentions for Savara. Viking Therapeutics' average media sentiment score of 0.33 beat Savara's score of 0.00 indicating that Viking Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viking Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Savara	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Viking Therapeutics has a beta of 0.66, suggesting that its stock price is 34% less volatile than the broader market. Comparatively, Savara has a beta of 0.24, suggesting that its stock price is 76% less volatile than the broader market.

Viking Therapeutics presently has a consensus target price of $93.60, suggesting a potential upside of 134.23%. Savara has a consensus target price of $10.14, suggesting a potential upside of 58.98%. Given Viking Therapeutics' higher probable upside, equities analysts plainly believe Viking Therapeutics is more favorable than Savara.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viking Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.79
Savara	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Viking Therapeutics' return on equity of -71.31% beat Savara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viking Therapeutics	N/A	-71.31%	-65.35%
Savara	N/A	-87.19%	-66.42%

Savara is trading at a lower price-to-earnings ratio than Viking Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.14	N/A
Savara	N/A	N/A	-$118.84M	-$0.56	N/A

Summary

Viking Therapeutics beats Savara on 9 of the 13 factors compared between the two stocks.

How does Savara compare to ACADIA Pharmaceuticals?

Savara (NASDAQ:SVRA) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, dividends, earnings, institutional ownership, risk, profitability, valuation and analyst recommendations.

ACADIA Pharmaceuticals has a net margin of 34.30% compared to Savara's net margin of 0.00%. ACADIA Pharmaceuticals' return on equity of 9.61% beat Savara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Savara	N/A	-87.19%	-66.42%
ACADIA Pharmaceuticals	34.30%	9.61%	7.07%

Savara has a beta of 0.24, meaning that its share price is 76% less volatile than the broader market. Comparatively, ACADIA Pharmaceuticals has a beta of 0.8, meaning that its share price is 20% less volatile than the broader market.

87.9% of Savara shares are owned by institutional investors. Comparatively, 96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. 5.3% of Savara shares are owned by company insiders. Comparatively, 26.2% of ACADIA Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, ACADIA Pharmaceuticals had 7 more articles in the media than Savara. MarketBeat recorded 8 mentions for ACADIA Pharmaceuticals and 1 mentions for Savara. ACADIA Pharmaceuticals' average media sentiment score of 1.06 beat Savara's score of 0.00 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Savara	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ACADIA Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Savara currently has a consensus target price of $10.14, indicating a potential upside of 58.98%. ACADIA Pharmaceuticals has a consensus target price of $32.94, indicating a potential upside of 26.70%. Given Savara's stronger consensus rating and higher possible upside, equities analysts clearly believe Savara is more favorable than ACADIA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Savara	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
ACADIA Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.65

ACADIA Pharmaceuticals has higher revenue and earnings than Savara. Savara is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Savara	N/A	N/A	-$118.84M	-$0.56	N/A
ACADIA Pharmaceuticals	$1.07B	4.16	$391M	$2.20	11.82

Summary

ACADIA Pharmaceuticals beats Savara on 13 of the 16 factors compared between the two stocks.

Get Savara News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SVRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SVRA vs. The Competition

Export

Metric	Savara	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.27B	$3.15B	$6.99B	$12.46B
Dividend Yield	N/A	2.05%	2.67%	7.39%
P/E Ratio	-11.39	20.08	27.17	24.24
Price / Sales	N/A	367.14	534.05	96.53
Price / Cash	N/A	57.46	49.24	56.96
Price / Book	6.38	4.42	10.83	6.38
Net Income	-$118.84M	$64.65M	$3.56B	$331.19M
7 Day Performance	5.28%	0.77%	0.81%	-1.84%
1 Month Performance	26.09%	7.22%	5.61%	0.85%
1 Year Performance	181.06%	28.94%	32.58%	22.18%

Savara Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SVRA Savara	1.712 of 5 stars	$6.38 +2.7%	$10.14 +59.0%	+165.4%	$1.27B	N/A	N/A	20
KNSA Kiniksa Pharmaceuticals International	3.1474 of 5 stars	$62.41 +5.4%	$62.71 +0.5%	+140.8%	$4.55B	$754.05M	69.34	220	Positive News
TNGX Tango Therapeutics	2.9017 of 5 stars	$32.56 +3.5%	$41.50 +27.5%	+454.7%	$4.55B	$62.38M	N/A	90
EWTX Edgewise Therapeutics	1.8482 of 5 stars	$40.92 -1.3%	$47.30 +15.6%	+242.0%	$4.46B	N/A	N/A	60	Analyst Forecast
VKTX Viking Therapeutics	2.5521 of 5 stars	$39.54 +3.9%	$93.60 +136.7%	+53.1%	$4.42B	N/A	N/A	20

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SVRA) was last updated on 7/8/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Savara (SVRA) Competitors

SVRA vs. KNSA, TNGX, EWTX, VKTX, and ACAD

How does Savara compare to Kiniksa Pharmaceuticals International?

Summary

How does Savara compare to Tango Therapeutics?

Summary

How does Savara compare to Edgewise Therapeutics?

Summary

How does Savara compare to Viking Therapeutics?

Summary

How does Savara compare to ACADIA Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SVRA vs. The Competition

Savara Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Savara (SVRA) Competitors

SVRA vs. KNSA, TNGX, EWTX, VKTX, and ACAD

How does Savara compare to Kiniksa Pharmaceuticals International?

Which has higher valuation & earnings, SVRA or KNSA?

Do institutionals & insiders have more ownership in SVRA or KNSA?

Is SVRA or KNSA more profitable?

Does the media prefer SVRA or KNSA?

Which has more volatility and risk, SVRA or KNSA?

Do analysts recommend SVRA or KNSA?

Summary

How does Savara compare to Tango Therapeutics?

Do analysts rate TNGX or SVRA?

Which has more risk & volatility, TNGX or SVRA?

Is TNGX or SVRA more profitable?

Does the media favor TNGX or SVRA?

Which has higher earnings and valuation, TNGX or SVRA?

Do institutionals & insiders hold more shares of TNGX or SVRA?

Summary

How does Savara compare to Edgewise Therapeutics?

Does the media favor SVRA or EWTX?

Is SVRA or EWTX more profitable?

Which has higher earnings and valuation, SVRA or EWTX?

Do insiders and institutionals have more ownership in SVRA or EWTX?

Do analysts rate SVRA or EWTX?

Which has more risk & volatility, SVRA or EWTX?

Summary

How does Savara compare to Viking Therapeutics?

Do insiders & institutionals hold more shares of VKTX or SVRA?

Does the media prefer VKTX or SVRA?

Which has more volatility & risk, VKTX or SVRA?

Do analysts rate VKTX or SVRA?

Is VKTX or SVRA more profitable?

Which has stronger earnings & valuation, VKTX or SVRA?

Summary

How does Savara compare to ACADIA Pharmaceuticals?

Is SVRA or ACAD more profitable?

Which has more volatility & risk, SVRA or ACAD?

Do institutionals and insiders believe in SVRA or ACAD?

Does the media refer more to SVRA or ACAD?

Do analysts recommend SVRA or ACAD?

Which has higher earnings & valuation, SVRA or ACAD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SVRA vs. The Competition

Savara Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools